Evolus, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EOLS research report →
Range $13 – $17
Price Chart
About the company
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation.
- CEO
- David Moatazedi
- IPO
- 2018
- Employees
- 353
- HQ
- Newport Beach, CA, US
Get TickerSpark's AI analysis on EOLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $431.55M
- P/E
- -14.95
- Fwd P/E
- 19.76
- PEG
- -0.20
- P/S
- 1.42
- P/B
- -12.22
- EV/EBITDA
- -132.69
- Div Yield
- 0.00%
- Gross Margin
- 65.91%
- Op Margin
- -5.69%
- Net Margin
- -9.56%
- ROE
- 103.19%
- ROIC
- -12.81%
Latest fiscal year · YoY change
- Revenue
- $297.18M+11.6%
- Gross Profit
- $192.76M+5.7%
- Op Income
- $-37,600,000
- Net Income
- $-51,641,000-2.4%
- EPS
- $-0.80+1.2%
- OCF Growth
- -134.8%
- FCF Growth
- -160.5%
- 52W High
- $9.31
- 52W Low
- $3.86
- 50D MA
- $7.47
- 200D MA
- $6.41
- Beta
- 1.34
- RSI (14)
- 40
- Avg Volume
- 922.16K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evolus posted 13% third-quarter revenue growth, its fourth straight quarter of positive adjusted EBITDA, and raised confidence in a broader multi-product injectable platform.· November 4, 2026
- Q3 revenue was $78 million, up 13% year over year, driven by 11% global toxin growth and nearly 40% growth in the new HA business.
- Adjusted EBITDA was positive for the fourth consecutive quarter, reaching $1.2 million in Q3 and $6.4 million in the first 9 months.
- Full-year revenue guidance was reaffirmed at $330 million to $337 million, with adjusted gross margin still expected at 67% to 67.5%.
- The company lowered full-year non-GAAP operating expense guidance to $210 million to $213 million from $212 million to $216 million.
- Management highlighted progress on the pipeline, including Sculpt under FDA review, Lips filing expected before year-end, and Profhilo development underway.
Third-quarter global net revenue was $78 million, up 13% year over year. Revenue included $70.1 million of global toxin revenue and $7.9 million from injectable HA gels. Reported gross margin was 65% and adjusted gross margin was 66.1%. Adjusted EBITDA was positive $1.2 million in Q3, improving by $4.2 million year over year; year-to-date adjusted EBITDA was $6.4 million versus a loss of $16.5 million a year ago. For the full year, Evolus reaffirmed revenue guidance of $330 million to $337 million, adjusted gross margin of 67% to 67.5%, and adjusted EBITDA margin of low- to mid-single digits, while lowering non-GAAP operating expense guidance to $210 million to $213 million. The company said Evolysse and Estyme injectable HA gels are still expected to contribute 10% to 12% of full-year revenue, and it assumes no revenue contribution from Evolysse Sculpt in 2026.
David Moatazedi framed the quarter as evidence that Evolus is becoming a broader global performance beauty company with multiple growth engines. He emphasized above-market growth, the fourth straight quarter of positive adjusted EBITDA, and the strategy of pairing commercial execution with pipeline expansion. His tone was confident and constructive, pointing to Jeuveau, Evolysse, Profhilo, and the hair-growth option as building blocks for a larger platform.
Tatjana Mitchell focused on operating leverage, noting 13% quarterly revenue growth, 14% year-to-date revenue growth to $235.2 million, and a 2.5% reduction in non-GAAP operating expenses year to date. She highlighted Q3 gross margin of 65% and adjusted gross margin of 66.1%, and said cash and cash equivalents ended the quarter at $41.7 million versus $45.2 million in Q2. She also said the company still has access to approximately $120 million of additional nondilutive capacity, expects fourth-quarter operating expenses to rise sequentially for seasonality, customer-event costs, and a $1.5 million option payment, and reaffirmed 2028 targets of $450 million to $500 million in revenue and 13% to 15% adjusted EBITDA margins.
Analysts pressed on the FDA untitled letter, Jeuveau growth, account expansion, and the competitive backdrop. Management said the FDA issue was isolated to a single Instagram post, was not a warning letter, was already removed, and did not affect the ability to promote Jeuveau. They also said Jeuveau delivered double-digit growth globally in the quarter and year to date, and that Evolysse is broadening adoption within existing and new accounts while the company tests a more closely bundled portfolio program in Q4. On account growth, management said the company is approaching 20,000 customers and believes the expanded portfolio is helping it engage higher-volume accounts and deepen penetration.
The quarter showed that Evolus can grow revenue while tightening expenses and producing positive adjusted EBITDA, which supports the company’s longer-term operating leverage story. Management also sounded upbeat about the HA launch, the early reception to Evolysse, and the prospect of additional launches, with Sculpt, Lips, and Profhilo extending the portfolio beyond Jeuveau.
The business still depends heavily on execution in a seasonal fourth quarter and on continued adoption of a relatively new filler portfolio. Management acknowledged sequential expense increases in Q4, a $1.5 million option payment tied to the hair-growth program, and that Sculpt is not assumed to contribute revenue in 2026, so near-term growth still leans on Jeuveau and current HA products. The FDA untitled letter also shows the company is not free of promotional scrutiny, even if management said the impact was limited.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.0%
- Shares Outstanding
- 66.19M
- Float Shares
- 47.66M
of shares held by institutions
168 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 6.24M | ▲ 642.67K |
| Blackrock, Inc. | 5.32M | ▲ 474.67K |
| Vanguard Group Inc | 3.34M | ▼ 87.14K |
| Braidwell LP | 3.16M | ▲ 50.00K |
| Frazier Life Sciences Management, L.P. | 2.63M | 0 |
| Perceptive Advisors LLC | 2.46M | ▲ 1.17M |
| Vanguard Capital Management LLC | 2.26M | ▼ 101.57K |
| State Street Corp | 1.85M | ▲ 156.81K |
| Millennium Management LLC | 1.79M | ▲ 326.77K |
| Geode Capital Management, LLC | 1.58M | ▼ 28.06K |
| Pinnacle Associates Ltd | 1.57M | ▲ 82.80K |
| Point72 Asset Management, L.P. | 1.51M | ▲ 1.51M |
Held by 146 ETFs
Biggest fund positions in EOLS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 2, 26 | MOATAZEDI DAVID | sell | 105,108 |
| Mar 20, 26 | Avelar Rui | sell | 3,119 |
| Mar 20, 26 | MOATAZEDI DAVID | sell | 13,669 |
| Mar 16, 26 | MOATAZEDI DAVID | other | 67,489 |
| Mar 17, 26 | MOATAZEDI DAVID | sell | 116,720 |
| Mar 16, 26 | MOATAZEDI DAVID | other | 67,489 |
| Mar 16, 26 | Avelar Rui | other | 8,804 |
| Mar 17, 26 | Avelar Rui | sell | 29,996 |
| Mar 16, 26 | Avelar Rui | other | 8,804 |
| Feb 17, 26 | Parschauer Karah Herdman | other | 45,559 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EOLS coverage
Recent articles, reports, and earnings notes.
No research on EOLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EOLS report →Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
defenseworld.net · Nov 17
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
marketbeat.com · Nov 15
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
globenewswire.com · Nov 10
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
prnewswire.com · Nov 5
Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
What Evolus (EOLS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.